Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737

Pharmaceutical Investing

Sierra Oncology released some preclinical data, which according to the company supports their current clinical development strategy.

Sierra Oncology (NASDAQ:SRRA) released some preclinical data, which according to the company supports their current clinical development strategy.
As quoted in the press release:

The results were presented in a poster on October 29th at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Philadelphia, Pennsylvania.

“The data generated from these experiments are consistent with recent findings from our research and demonstrate that a potent and selective Chk1 inhibitor such as SRA737 can effectively synergize with sub-therapeutic doses of gemcitabine to induce replication catastrophe and tumor cell death,” said Dr. Alan R. Eastman, Professor at the Geisel School of Medicine at Dartmouth and the founding Director of the Molecular Therapeutics Research Program of the Norris Cotton Cancer Center at Dartmouth–Hitchcock.

Click here to read the full press release.

Source: www.newswire.ca

cancer cancer therapeutics oncology preclinical data sierra oncology therapeutics Pharmaceutical Investing